Abbreviations GLP-1: Glucagon Like Peptide-1 CV: Cardio Vascular DPP-4: DiPeptidylPeptidase-4 USFDA: United States Food & Drug Administration Aib: 2-Aminoisobutyric acid SNAC: Sodium-N-[8-(2-hydroxybenzoyl)amino]caprylate SUSTAIN: Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes FPG: Fasting Plasma Glucose HOMA-B: Homeostasis model assessment of -cell function ER: Extended release DXA: Dual energy X-ray Absorptiometry OAD: Oral Antidiabetic Drugs SGLT-2: Sodium GLucose co-Transporter-2 SMBG: Self-Monitoring of Blood Glucose PIONEER: Peptide Innovation for Early Diabetes Treatment EMA: European Medicines Agency References Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE
However, the importance of -fetoprotein in protecting female fetuses from behavioral masculinization and infertility at the hands of maternal estrogens is definitively established by observation of both those end points in female neonates with a null mutation rendering them incapable of -fetoprotein production (15)
Identity and purity of components are typically verified by HPLC and mass spectrometry
Furthermore, their multifaceted mechanisms of action suggest potential applications beyond traditional metabolic disorders
